From January 2023, Cephalalgia will be an online, Gold Open Access journal – for more information visit, the FAQs page.
To submit your manuscript online, please click here:
Cephalalgia contains original papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications.
Published monthly on behalf of the International Headache Society. Readers receive timely cutting edge original articles, editorials, reviews, letters and clinical correspondence on both clinical and basic research. Subscribers also receive themed Supplements and news on events within the headache community.
Recently published topics include:
· diagnosis and management of primary and secondary headaches and related syndromes
· medico-legal aspects
This journal is a member of the Committee on Publication Ethics (COPE).
Previous Editors of the Journal:
Ottar Sjaastad (Founding Editor), Marcia Wilkinson, K Michael Welch, Peter J Goadsby, David Dodick.
From January 2023, Cephalalgia will be an online, Gold Open Access journal – for more information visit, the FAQs page.
Cephalalgiacontains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications.
Published monthly on behalf of the International Headache Society. Readers receive timely cutting edge original articles, editorials, reviews, letters and clinical correspondence on both clinical and basic research. Subscribers also receive themed Supplements and news on events within the headache community. Recently published topics include:
- diagnosis and management of primary and secondary headaches and related syndromes
- medico-legal aspects
This journal is a member of the Committee on Publication Ethics (COPE).
|Arne May, MD, PhD||Department of Systems Neuroscience, University Clinic Hamburg Eppendorf (UKE) Hamburg, Germany|
|Frank Andrasik, PhD||University of Memphis, USA|
|Messoud Ashina, MD, PhD, DMSc||Glostrup Hospital, University of Copenhagen, Denmark|
|Rafael Benoliel, OM||Rutgers University, USA|
|Rami Burstein, PhD||Beth Israel Deaconess Medical Center, USA|
|Andrew C. Charles, MD||University of California, USA|
|Gianluca Coppola, MD, PhD||Sapienza University of Rome Polo Pontino, Italy|
|Hans-Christoph Diener, MD, PhD||University Essen, Germany|
|Anne Ducros, MD, PhD||Montpellier University Hospital, Montpellier, France|
|Stefan Evers, MD, PhD||University of Münster, Germany|
|Larus S. Gudmundsson, MSc, PhD||University of Iceland, Iceland|
|Andrew Hershey, MD, PhD, FAHS||University of Cincinnati, USA|
|Jan Hoffmann, MD, PhD||Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK|
|Philip R. Holland, BSc, PhD||King's College London, UK|
|Timothy T. Houle, PhD||Harvard Medical School, USA|
|Mi Ji Lee, MD, PhD||Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea|
|Karl Messlinger, Dipl. Biol. Dr. med. Dr. med habil||University of Erlangen Nurenberg, Germany|
|Kuan-Po Peng, MD||Department of Systems Neuroscience, University Clinic Hamburg Eppendorf (UKE), Germany|
|Patricia Pozo-Rosich, MD, PhD||Vall d'Hebron University Hospital, Spain|
|Todd Schwedt, MD||Mayo Clinic College of Medicine, USA|
|Cristina Tassorelli, MD, PhD, FEAN||Neurological Institute C Mondino Foundation, Italy|
|Erling A. Tronvik, MD||Norwegian University of Science and Technology, Norway|
|Shuu-Jiun Wang, MD||Taipei Veterans General Hospital, Taiwan|
|Alessandro S. Zagami, MD||Prince of Wales Hospital, Institute of Neurological Sciences, Sydney, Australia|
|Wendy Krank||Managing Editor, USA|
|James S. McGinley, PhD||Vector Psychometric Group, USA|
|Peter J. Koehler, MD, PhD, FAAN||Faculty of Health, Medicine and Life Studies, Maastricht University, Netherlands|
|Faisal Mohammad Amin, MD, PhD||Glostrup Hospital, University of Copenhagen, Denmark|
|Edoardo Caronna, MD, PhD||Vall d'Hebron Research Institute, Spain|
|Francesca Puledda, MD, PhD||King's College London, UK|
|Marta Vila-Pueyo, PhD||Vall d'Hebron Research Institute, Spain|
|Peter J. Goadsby, MD, PhD, DSc, FRACP, FRCP||King's College London, UK|
|David W. Dodick, MD, FAAN||Mayo Clinic College of Medicine, USA|
Cephalalgia is a medical-neurological journal in the field of headache research, and is the official journal of the International Headache Society.
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/cephalalgia to upload your manuscript.
Only manuscripts of sufficient quality that meet the aims and scope of Cephalalgia will be reviewed.
Please note that manuscripts not conforming to these guidelines may be returned.
The Journal requires that studies on headache and cervical pain adhere to the terminology, diagnostic disorders, and criteria within the ICHD (Cephalalgia. 2018 Jan;38(1):1-211.) and studies on facial pain adhere to the terminology, diagnostic disorders, and criteria within ICOP (Cephalalgia. 2020 Feb;40(2):129-221) .
From January 2023, Cephalalgia will be an online, Gold Open Access journal. An Article Processing Charge (APC) will be added for all articles submitted after 1st September 2022, should they be accepted. This will be priced at 3000 USD, discounted to 2500 USD for the first two years until 1st January 2025. Members of the International Headache Society will be able to pay a discounted rate of 1500 USD; society membership requirement for ACP is first *AND* last author are IHS members, and the designation selected at the time of submission. More information regarding Open Access can be found here.
As part of the submission process, you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that Cephalalgia will consider submissions of papers that have been posted on preprint servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the Journal. If the article is accepted for publication, the author may re-use their work according to the Journal's author archiving policy.
If your paper is accepted, you must include a link on your preprint to the final version of your paper.
If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal
Contact Cephalalgia - email: firstname.lastname@example.org
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.2.1 Methodological/Statistical Guidelines
1.3 Writing your paper
1.3.1 Make your article discoverable
- Editorial policies
2.1 Peer review policy
2.1.1 Fast-track review
2.3.1 Third party submissions
2.3.2 Medical Writers
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
2.9 Research Data
- Publishing policies
3.1 Publication ethics
3.1.2 Prior publication
3.2 Contributor's publishing agreement
3.3 Open access and author archiving
- Preparing your manuscript
4.1.1 Title page
4.1.2 Structuring your abstract
4.1.3 Study highlights bullet points
4.2 Artwork, figures and other graphics
4.3 Supplemental material
4.4 Reference style
4.5 English language editing services
- Submitting your manuscript
5.2 Information required for completing your submission
- On acceptance and publication
6.1 SAGE Production
6.2 Online First publication
6.3 Access to your published article
6.4 Promoting your article
- Further information
7.1 Appealing the publication decision
Before submitting your manuscript to Cephalalgia, please ensure you have read the Aims & Scope.
The journal provides an international forum for original research papers, review articles and brief communications. The Journal considers the following kinds of article for publication:
They are short, invited opinion pieces that discuss an issue of immediate importance to the research community. Editorials should have fewer than 1000 words total, no abstract, a minimal number of references up to 5, and no figures or tables.
This type of articles are opinion pieces grounded in evidence. These articles should be 500 words in length (main text). A structured abstract up to 200 words in length is required. The reference list should be selective, containing no more than 3 selected references. Up to 1 figure and 1 table can be included.
Review articles should be up to 4,000 words in length (main text). Longer articles may be acceptable in special cases but should be discussed with the Editor prior to submission. A structured abstract up to 200 words in length is required. The reference list should be selective, containing about 100 selected references. Articles should be liberally illustrated with figures and diagrams (colour encouraged). There is no strict upper limit of figures and tables allowed.
Cephalalgia allows two different types of reviews: narrative review or systemic review, the latter of which must follow the PRISMA Reporting Guidelines, and in the case of meta-analysis, the MOOSE guideline. You are required to completed and uploaded the pertinent guidelines into the manuscript files system
Original research papers
These articles should be 3,000-3,500 words in length (main text). A structured abstract up to 200 words in length is required. The reference list should be selective, containing no more than about 35 selected references. Articles should be liberally illustrated with figures and diagrams (colour encouraged). There is no strict upper limit of figures and tables allowed. Usually, up to 6-8 individual figures and tables can be included.
Based on the type of original research, the pertinent checklist MUST be completed and uploaded into the manuscript files system: Reports of clinical trials should adhere to the tenets of the CONSORT statement. A flow chart MUST be provided describing the progress of patients through the trial. Reports of observational studies should adhere to the tenets of the STROBE statement. Reports of animal studies should adhere to the tenets of the ARRIVE statement.
Brief reports are short articles that deals with : (i) re-analyse part of an article that has previously been published; (ii) present findings, or discuss issues of particular interest to the community, but are not suitable as a standard research article; (iii) case report or small case series. These articles should be in principle around up to 1,500 words in length (main text). A structured abstract up to 150 words in length is required. The reference list should be selective, containing no more than 12 selected references. Up to 2 figures and 1 table can be included. Based on the type of research, the pertinent checklist MUST be completed and uploaded following those mentioned in the “Original research papers”. Case reports should adhere to the tenets of the CARE statement, and CARE checklist MUST be completed and uploaded following those mentioned in the “Original research papers”.
Letter to the Editor
A Letter to the editor should be an article that raises issues of general interest to the broad readership of Cephalalgia. In case of re-analysis of a previously published article in Cephalalgia or brief research findings, please use “Brief reports” instead. Letters to the editor may be edited for clarity or length and may be subject to peer review at the editors' discretion. These papers should be up to 750 words in length, and no abstract is needed. The reference list should be selective, containing no more than 5 selected references.
Ethics or Institutional Review Board Approval: Please clearly indicate that the study obtained appropriate approval (or a statement and explanation of why it was not required), including the name of the ethics committee(s) or institutional review board(s), the number/ID of the approval(s). For human studies, please also add a statement that participants gave informed consent before taking part.
Study Protocol: If your study protocol is registered (ClinicalTrial.gov, etc.), please provide the registration number (required for intervention studies). The trial registration number should appear in the manuscript following the abstract. We encourage the registration of observational study protocols.
Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. General principles for reporting statistical results should follow the SAMPL Guideline.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
For information and guidance on how best to title your article, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
Cephalalgia operates a conventional single-anonymize reviewing policy in which the reviewer's name is always concealed from the submitting author.
Generally, each manuscript is reviewed by at least two referees. All manuscripts are reviewed as rapidly as possible, and an editorial decision is generally reached within 5-6 weeks of submission.
Obligate external peer-review is not mandatory. After review by the Editor-in-Chief and Associate Editor, a decision is made whether to send the manuscript for external peer review.
In addition, case reports may be reviewed by the Editor-in-Chief and Associate Editor without external peer review or with only 1 external peer reviewer.
Please note that in any papers where an editor from the journal is an author the processing of the manuscript is handled by a different Associate Editor and the Editor is totally anonymized from the procedure, has no influence on the final decision, and will never have access to the peer reviewer details.
Cephalalgia provides a fast-track review option whereby two Associate Editors may review a manuscript within 72 hours and on-line publication occurs within 4 weeks of acceptance.
The cost of such rapid review is $900 USD. This payment is to cover the time of the Associate Editors. Please note that this payment is strictly to facilitate the rapid review process and does not in any way guarantee acceptance or publication of your article.
If you wish to make use of this facility, please choose the ‘fast track review’ option in the article type dropdown menu when submitting your article. If you choose the ‘fast-track’ review option you are agreeing to pay the $900.00 USD for this service.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
- Disclose this type of editorial assistance – including the individual’s name, company and level of input
- Identify any entities that paid for this assistance
- Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g., conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
Individuals who provided writing assistance, e.g., from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Cephalalgia requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Cephalalgia to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
Cephalalgia conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline. If your research involves animals, you will be asked to confirm that you have carefully read and adhered to the ARRIVE guidelines.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
At SAGE we are committed to facilitating openness, transparency and reproducibility of research. Where relevant, The Journal encourages authors to share their research data in a suitable public repository subject to ethical considerations and where data is included, to add a data accessibility statement in their manuscript file. Authors should also follow data citation principles. For more information please visit the SAGE Author Gateway, which includes information about SAGE’s partnership with the data repository Figshare.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Cephalalgia and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information, please visit the SAGE Author Gateway.
Papers submitted after 1st September 2022, subject to acceptance, will be published in Gold Open Access Cephalalgia from 2023. For more information relating to Cephalalgia becoming open access, visit the FAQs page. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
The preferred format for your manuscript is Word. Word templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
The text should be double-spaced throughout and with a minimum of 3cm for left- and right-hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. The font colour is black, please do not use coloured font. SI units should be used throughout the text.
Only electronic files conforming to the journal's guidelines will be accepted. The preferred format for the text and tables of your manuscript is Word. All figures/images and tables must be uploaded as separate files, whereas the figure legends remain in the main body file. Please note that Cephalalgia does not have a file category called "box". The file categories are main body, tables, figures, and supporting documents. Do not upload tables as screenshots. Please also refer to additional guidelines on submitting artwork and supporting files below.
The first page(s) of your manuscript no matter the submission category all manuscripts are required to include a title page with the following information:
- All author names and affiliations,
- Corresponding author contact details,
- Structured abstract (if applicable to manuscript type),
- Trial Registration (if applicable to manuscript type),
- Key words.
Given that Cephalalgia is a journal devoted to headache and facial pain, readers are familiar with these diseases. The journal author guidelines require a structured abstract using 3 or 4 paragraphs without cite of references or abbreviations. Common headings of each paragraph include: Background/Hypothesis, Methods, Results, Conclusion/Interpretation. Word count is based on the types of articles and the information can be found in 1.2 Article Types. Any papers received without a structured abstract will be returned to the corresponding author.
Cephalalgia publishes original papers on all aspects of headache and facial pain. For original research papers, in the manuscript, you are required to include two to five bullet points with a word limit of 60 in total clearly summarizing the highlights of your research. These bullet points will appear at the end of your manuscript following the conclusion and prior to the reference list.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Please note that for Cephalalgia the main body of your article should not contain figures or tables.
Figures supplied in colour will appear in colour online and in the print issue. There is no charge for reproducing figures in colour in the printed version.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Cephalalgia operates a SAGE Vancouver reference style. Click here to review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
Please include only one reference list. The source for any table and/or figures should be included in the main reference list and not as separate references.
All tables and figures should be numbered consecutively and cited in the text as Table 1, Table 2 etc. or Figure 1, Figure 2 etc. (Table and Figure should be spelled out in full, not abbreviated).
Examples: figures/tables should be referenced in the text as follows:
Figure 1, or Figures 1 and 2, or Figures 2 to 4, or Figure 1(a) and (b), or Figure 2(a) to (c).
Table 1, or Table 2 and 2, or Table 2 t o4, or Table 1(a) and (b), or Table 2(a) to(c).
Where the figure citation is not part of the sentence it should be placed in parentheses.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Before submitting your manuscript, please ensure you carefully read and adhere to all the guidelines and instructions to authors provided below. Manuscripts not conforming to these guidelines may be returned to your Author Centre. Common reasons include: inaccurate title page format; the lack of corresponding reporting guidelines, wrongful placement of Tables and Figures.
Specifically, please upload the elements of the manuscripts as single file(s) and in the correct format using the file extension guide herein below:
Document Files: .doc, .docx, .xls, .xlsx, .rtf.
Image Files: .PDF, .jpg, .jpeg, .png, .tiff.
Follow these recommendations to ensure that your files will properly convert to HTML and PDF:
Videos: .mp4, .mov
- File names do not include special characters or spaces, except for “_” or “-“;
- File names are less than 20 characters long;
- File names follow a simple format, i.e., "mymanuscript.doc".
- Do not embed fonts;
- Remove macros;
- Remove hyperlinks from the main body;
- Remove Field Codes (placeholders in Microsoft Word for data that might change in a document);
- Verify your spreadsheet files have only a single tab;
- Reminder, use short file names without symbols.
- Remove thumbnails from image files;
- Verify your images are in single, flattened layer (e.g., no multi-pages TIFs);
- Images must arrive as 300 dpi.
Cephalalgia is hosted on SAGE track, a web based online submission and peer review system powered by ScholarOne© Manuscripts. Please read the Manuscript Submission guidelines below, and then simply visit http://mc.manuscriptcentral.com/cephalalgia to login and submit your article online.
Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. Please ensure the author account data is accurate before proceeding to the manuscript submission. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
If you would like to discuss your manuscript prior to submission, please refer to the contact details below.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.
We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.
Find the ORCID IDs of the Editorial Board here.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage, please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. ‘Additionally, please ensure you use the generic names for substances, drugs or devices rather than the trade name. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.
SAGE provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Cephalalgia editorial office as follows:
Cephalalgia Editorial Office